Technology area: Biotechnology & Pharmaceuticals
13 pending office actions • 10 clients • 13 examiners • 12 art units • 0 of 13 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Pearl Cohen Zedek Latzer Baratz LLP focuses on Biotechnology & Pharmaceuticals and has 14 pending office actions. Its career record includes 9943 applications, supplying a broad historical base for interpreting the active docket.
The resolved allowance rate is 79.35%, and the average office actions per allowance is 3.6. The allowance rate indicates the recorded outcome among resolved applications, while the action average reflects the examination activity associated with allowances. For practitioners, these measures provide a way to consider current response obligations alongside the firm’s historical prosecution pattern in a technically specialized area.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (15%) |
| §103 only | 3 (23%) |
| Double-patenting + other | 1 (8%) |
| Multi-statute (no §101) | 7 (54%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BADER, ROBERT N. | 1 | 44.8% | +25.8% |
| ABUZEINEH, HANAN ISAM | 1 | 51.9% | +54.2% |
| NGUYEN, PHU K | 1 | 85.9% | +7.9% |
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
| TRAN, VINCENT HUY | 1 | 86.6% | +9.8% |
| LEY, SALLY THI | 1 | 23.9% | +15.7% |
| SCHULTZHAUS, JANNA NICOLE | 1 | 35.4% | +38.2% |
| TCHERKASSKAYA, OLGA V | 1 | 55.5% | +46.4% |
| KAMM, JUDITH MARIE | 1 | 42.9% | +57.1% |
| MIDDLETON, DANAYA L | 1 | 49.5% | +48.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18396854 | SYSTEM AND METHOD FOR TRAINING AND USING AN IMPLICIT REPRESENTATION NETWORK FOR REPRESENTING THREE DIMENSIONAL OBJECTS | NGUYEN, PHU K | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17614563 | ARTIFICIAL RECEPTORS, RECOMBINANT CELLS COMPRISING THEREOF, METHODS FOR THEIR PREPARATION, AND METHOD OF USING THEREOF | IVICH, FERNANDO NMN | 168d overdue |
| 17628112 | MEDICINAL AND/OR PHARMACEUTICAL COMPOSITIONS FOR INTRAVESICAL INSTILLATION, PREPARATION AND USE THEREOF | SABILA, MERCY HELLEN | 14d |
| 18383256 | AGENTS AND METHODS FOR PREVENTING AND TREATING SKELETAL MUSCLE DISEASES | LEE, WILLIAM Y | 48d |
| 18136072 | QUANTIFYING THE RESPONSE-SPECIFICITY OF MONONUCLEAR CELLS AND USES THEREOF | SCHULTZHAUS, JANNA NICOLE | 63d |
| 17642515 | IMMUNOACTIVE MICROPARTICLES AND USES THEREOF | MIDDLETON, DANAYA L | 70d |
| 18591919 | GRAPHICS TEXTURE PROCESSING | BADER, ROBERT N. | — |
| 18576102 | METHODS OF GENERATING MESENCHYAL STEM CELLS WHICH SECRETE NEUROTROPHIC FACTORS IN A BIOREACTOR SYSTEM | ABUZEINEH, HANAN ISAM | — |
| 18450641 | APPARATUS AND METHOD FOR IDENTIFYING CRITICAL FEATURES USING MACHINE LEARNING | TRAN, VINCENT HUY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18013508 | GSK3 INHIBITOR-LOADED NANO FORMULATIONS AS A CANCER IMMUNOTHERAPEUTIC | KAMM, JUDITH MARIE | 41d |
| 18383256 | AGENTS AND METHODS FOR PREVENTING AND TREATING SKELETAL MUSCLE DISEASES | LEE, WILLIAM Y | 48d |
| 18136072 | QUANTIFYING THE RESPONSE-SPECIFICITY OF MONONUCLEAR CELLS AND USES THEREOF | SCHULTZHAUS, JANNA NICOLE | 63d |
| 17642515 | IMMUNOACTIVE MICROPARTICLES AND USES THEREOF | MIDDLETON, DANAYA L | 70d |
| 18591919 | GRAPHICS TEXTURE PROCESSING | BADER, ROBERT N. | — |
| 18576102 | METHODS OF GENERATING MESENCHYAL STEM CELLS WHICH SECRETE NEUROTROPHIC FACTORS IN A BIOREACTOR SYSTEM | ABUZEINEH, HANAN ISAM | — |
| 18273255 | METHOD OF AND SYSTEM FOR PROVIDING AN AGGREGATED MACHINE LEARNING MODEL IN A FEDERATED LEARNING ENVIRONMENT AND DETERMINING RELATIVE CONTRIBUTION OF LOCAL DATASETS THERETO | LEY, SALLY THI | — |
| 18128328 | STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOF | TCHERKASSKAYA, OLGA V | — |
| Client (Assignee) | Pending OAs |
|---|---|
| University of California | 4 |
| SoftBank | 1 |
| BRAINSTORM CELL THERAPEUTICS LTD. | 1 |
| De-Identification Ltd. | 1 |
| MARKFORGED, INC. | 1 |
| Concordia University Inc. | 1 |
| Mayne Pharma LLC | 1 |
| CORNEAT VISION LTD | 1 |
| Peter BIRINYI | 1 |
| Weizmann Institute of Science | 1 |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 2611 | 1 |
| 1633 | 1 |
| 2616 | 1 |
| 1623 | 1 |
| 2115 | 1 |
| 2147 | 1 |
| 1685 | 1 |
| 1611 | 1 |
| 1674 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18591919 | GRAPHICS TEXTURE PROCESSING | Arm Limited | BADER, ROBERT N. | 2611 | §103§112 | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18576102 | METHODS OF GENERATING MESENCHYAL STEM CELLS WHICH SECRETE NEUROTROPHIC FACTORS IN A BIOREACTOR SYSTEM | BRAINSTORM CELL THERAPEUTICS LTD. | ABUZEINEH, HANAN ISAM | 1633 | §102§103§112 | Non-Final OA | — | Pending | Jan 03, 2024 |
| 18396854 | SYSTEM AND METHOD FOR TRAINING AND USING AN IMPLICIT REPRESENTATION NETWORK FOR REPRESENTING THREE DIMENSIONAL OBJECTS | De-Identification Ltd. | NGUYEN, PHU K | 2616 | §103 | Non-Final OA | — | Pending | Dec 27, 2023 |
| 18383256 | AGENTS AND METHODS FOR PREVENTING AND TREATING SKELETAL MUSCLE DISEASES | The Regents of the University of California | LEE, WILLIAM Y | 1623 | §102§103§112 | Non-Final OA | 48d | Pending | Oct 24, 2023 |
| 18450641 | APPARATUS AND METHOD FOR IDENTIFYING CRITICAL FEATURES USING MACHINE LEARNING | Markforged, Inc. | TRAN, VINCENT HUY | 2115 | §101§102§103 | Non-Final OA | — | Pending | Aug 16, 2023 |
| 18273255 | METHOD OF AND SYSTEM FOR PROVIDING AN AGGREGATED MACHINE LEARNING MODEL IN A FEDERATED LEARNING ENVIRONMENT AND DETERMINING RELATIVE CONTRIBUTION OF LOCAL DATASETS THERETO | Concordia University Inc. | LEY, SALLY THI | 2147 | §103 | Non-Final OA | — | Pending | Jul 19, 2023 |
| 18136072 | QUANTIFYING THE RESPONSE-SPECIFICITY OF MONONUCLEAR CELLS AND USES THEREOF | The Regents of the University of California | SCHULTZHAUS, JANNA NICOLE | 1685 | §101§103§112 | Non-Final OA | 63d | Pending | Apr 18, 2023 |
| 18128328 | STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOF | Mayne Pharma LLC | TCHERKASSKAYA, OLGA V | 1615 | §103§112DP | Final Rejection | — | Pending | Mar 30, 2023 |
| 18013508 | GSK3 INHIBITOR-LOADED NANO FORMULATIONS AS A CANCER IMMUNOTHERAPEUTIC | The Regents of the University of California | KAMM, JUDITH MARIE | 1611 | §103Other | Final Rejection | 41d | Pending | Dec 28, 2022 |
| 17642515 | IMMUNOACTIVE MICROPARTICLES AND USES THEREOF | The Regents of the University of California | MIDDLETON, DANAYA L | 1674 | §102§112 | Final Rejection | 70d | Pending | Mar 11, 2022 |
| 17640920 | GRAFT PATCH FOR THE TREATMENT OF MYOPIA AND OPHTHALMIC CONDITIONS | Corneat Vision Ltd. | TRUONG, QUANGLONG N | 1615 | §103§112 | Non-Final OA | — | Pending | Mar 07, 2022 |
| 17628112 | MEDICINAL AND/OR PHARMACEUTICAL COMPOSITIONS FOR INTRAVESICAL INSTILLATION, PREPARATION AND USE THEREOF | Peter Birinyi | SABILA, MERCY HELLEN | 1654 | §103§112 | Final Rejection | 14d | Pending | Jan 18, 2022 |
| 17614563 | ARTIFICIAL RECEPTORS, RECOMBINANT CELLS COMPRISING THEREOF, METHODS FOR THEIR PREPARATION, AND METHOD OF USING THEREOF | Yeda Research And Development Co. Ltd. | IVICH, FERNANDO NMN | 1678 | §103§112Other | Final Rejection | 168d overdue | Pending | Nov 29, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial79.3% of resolved applications prosecuted by Pearl Cohen Zedek Latzer Baratz, LLP were allowed, across 9,943 applications in USPTO records.
3.60 office actions per allowed application on average.
13 pending office actions as of October 2026, for 10 clients, before 13 examiners in 12 art units.
